Overview

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer